ISG15: In Sickness and in Health

Trends in Immunology

Volumn 38, Issue 2, 2017, Pages 79-93

  Hermann, Mark ^a   Bogunovic, Dusan ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ISG15 PROTEIN; PROTEIN; UNCLASSIFIED DRUG; CYTOKINE; INTERFERON; ISG15 PROTEIN, HUMAN; UBIQUITIN;

CONJUGATION; GENE EXPRESSION; GENERAL ASPECTS OF DISEASE; HEALTH; HUMAN; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PROTEIN DEFICIENCY; REVIEW; ANIMAL; AUTOIMMUNITY; BACTERIAL INFECTION; GENE EXPRESSION REGULATION; GENETICS; IMMUNITY; IMMUNOLOGY; MOUSE; MYCOBACTERIACEAE; SPECIES DIFFERENCE; VIRUS INFECTION;

ANIMALS; AUTOIMMUNITY; BACTERIAL INFECTIONS; CYTOKINES; GENE EXPRESSION REGULATION; HUMANS; IMMUNITY; INTERFERON TYPE I; MICE; MYCOBACTERIACEAE; SPECIES SPECIFICITY; UBIQUITINS; VIRUS DISEASES;

EID: 85006986748     PISSN: 14714906     EISSN: 14714981     Source Type: Journal    
DOI: 10.1016/j.it.2016.11.001     Document Type: Review

References (79)

1. 1 Schoggins, J.W., Rice, C.M., Interferon-stimulated genes and their antiviral effector functions. Curr. Opin. Virol. 1 (2011), 519–525.
2. 2 Ivashkiv, L.B., Donlin, L.T., Regulation of type I interferon responses. Nat. Rev. Immunol. 14 (2014), 36–49.
3. 3 Levy, D.E., et al. Durbin, Induction and function of type I and III interferon in response to viral infection. Curr. Opin. Virol. 1 (2011), 476–486.
4. 4 Ershov, F.I., et al. Comparative analysis of interferon and antiviral protein messenger RNAs. Acta Virol. 23 (1979), 32–39.
5. 5 Farrell, P.J., et al. Accumulation of an mRNA and protein in interferon-treated Ehrlich ascites tumour cells. Nature 279 (1979), 523–525.
6. 6 Blomstrom, D.C., et al. Molecular characterization of the interferon-induced 15-kDa protein. Molecular cloning and nucleotide and amino acid sequence. J. Biol. Chem. 261 (1986), 8811–8816.
7. 7 Korant, B.D., et al. Interferon-induced proteins. Purification and characterization of a 15,000-dalton protein from human and bovine cells induced by interferon. J. Biol. Chem. 259 (1984), 14835–14839.
8. 8 Knight, E. Jr., et al. A 15-kDa interferon-induced protein is derived by COOH-terminal processing of a 17-kDa precursor. J. Biol. Chem. 263 (1988), 4520–4522.
9. 9 Haas, A.L., et al. Interferon induces a 15-kilodalton protein exhibiting marked homology to ubiquitin. J. Biol. Chem. 262 (1987), 11315–11323.
10. 10 Knight, E. Jr., Cordova, B., IFN-induced 15-kDa protein is released from human lymphocytes and monocytes. J. Immunol. 146 (1991), 2280–2284.
11. 11 Loeb, K.R., Haas, A.L., The interferon-inducible 15-kDa ubiquitin homolog conjugates to intracellular proteins. J. Biol. Chem. 267 (1992), 7806–7813.
12. 12 Zhang, D., Zhang, D.E., Interferon-stimulated gene 15 and the protein ISGylation system. J. Interferon Cytokine Res. 31 (2011), 119–130.
13. 13 Dao, C.T., Zhang, D.E., ISG15: a ubiquitin-like enigma. Front. Biosci. 10 (2005), 2701–2722.
14. 14 Potter, J.L., et al. Precursor processing of pro-ISG15/UCRP, an interferon-beta-induced ubiquitin-like protein. J. Biol. Chem. 274 (1999), 25061–25068.
15. 15 Narasimhan, J., et al. Crystal structure of the interferon-induced ubiquitin-like protein ISG15. J. Biol. Chem. 280 (2005), 27356–27365.
16. 16 Yuan, W., Krug, R.M., Influenza B virus NS1 protein inhibits conjugation of the interferon (IFN)-induced ubiquitin-like ISG15 protein. EMBO J. 20 (2001), 362–371.
17. 17 Zhao, C., et al. The UbcH8 ubiquitin E2 enzyme is also the E2 enzyme for ISG15, an IFN-alpha/beta-induced ubiquitin-like protein. Proc. Natl. Acad. Sci. U.S.A. 101 (2004), 7578–8752.
18. 18 Kim, K.I., et al. Interferon-inducible ubiquitin E2, Ubc8, is a conjugating enzyme for protein ISGylation. Mol. Cell. Biol. 24 (2004), 9592–9600.
19. 19 Okumura, F., et al. ISG15 modification of the eIF4E cognate 4EHP enhances cap structure-binding activity of 4EHP. Genes Dev. 21 (2007), 255–260.
20. 20 Tan, N.G., et al. Human homologue of ariadne promotes the ubiquitylation of translation initiation factor 4E homologous protein, 4EHP. FEBS Lett. 554 (2003), 501–504.
21. 21 Zou, W., Zhang, D.E., The interferon-inducible ubiquitin-protein isopeptide ligase (E3) EFP also functions as an ISG15 E3 ligase. J. Biol. Chem. 281 (2006), 3989–3994.
22. 22 Zou, W., et al. Negative regulation of ISG15 E3 ligase EFP through its autoISGylation. Biochem. Biophys. Res. Commun. 354 (2007), 321–327.
23. 23 Dastur, A., et al. Herc5, an interferon-induced HECT E3 enzyme, is required for conjugation of ISG15 in human cells. J. Biol. Chem. 281 (2006), 4334–4338.
24. 24 Wong, J.J., et al. HERC5 is an IFN-induced HECT-type E3 protein ligase that mediates type I IFN-induced ISGylation of protein targets. Proc. Natl. Acad. Sci. U.S.A. 103 (2006), 10735–10740.
25. 25 Durfee, L.A., et al. The ISG15 conjugation system broadly targets newly synthesized proteins: implications for the antiviral function of ISG15. Mol. Cell 38 (2010), 722–732.
26. 26 Oudshoorn, D., et al. HERC6 is the main E3 ligase for global ISG15 conjugation in mouse cells. PLoS ONE, 7, 2012, e29870.
27. 27 D'Cunha, J., et al. In vitro and in vivo secretion of human ISG15, an IFN-induced immunomodulatory cytokine. J. Immunol. 157 (1996), 4100–4108.
28. 28 Recht, M., et al. A human 15-kDa IFN-induced protein induces the secretion of IFN-gamma. J. Immunol. 147 (1991), 2617–2623.
29. 29 Bogunovic, D., et al. Mycobacterial disease and impaired IFN-gamma immunity in humans with inherited ISG15 deficiency. Science 337 (2012), 1684–1688.
30. 30 Zhang, X., et al. Human intracellular ISG15 prevents interferon-alpha/beta over-amplification and auto-inflammation. Nature 517 (2015), 89–93.
31. 31 Speer, S.D., et al. ISG15 deficiency and increased viral resistance in humans but not mice. Nat. Commun., 7, 2016, 11496.
32. 32 Bustamante, J., et al. Mendelian susceptibility to mycobacterial disease: genetic, immunological, and clinical features of inborn errors of IFN-gamma immunity. Semin. Immunol. 26 (2014), 454–470.
33. 33 Casanova, J.L., Abel, L., Genetic dissection of immunity to mycobacteria: the human model. Annu. Rev. Immunol. 20 (2002), 581–620.
34. 34 Manyam, B.V., What is and what is not ‘Fahr's disease’. Parkinsonism Relat. Disord. 11 (2005), 73–80.
35. 35 Wang, C., et al. Mutations in SLC20A2 link familial idiopathic basal ganglia calcification with phosphate homeostasis. Nat. Genet. 44 (2012), 254–256.
36. 36 Crow, Y.J., Rehwinkel, J., Aicardi-Goutieres syndrome and related phenotypes: linking nucleic acid metabolism with autoimmunity. Hum. Mol. Genet. 18 (2009), R130–R136.
37. 37 Briggs, T.A., et al. Tartrate-resistant acid phosphatase deficiency causes a bone dysplasia with autoimmunity and a type I interferon expression signature. Nat. Genet. 43 (2011), 127–131.
38. 38 Crow, Y.J., Manel, N., Aicardi-Goutieres syndrome and the type I interferonopathies. Nat. Rev. Immunol. 15 (2015), 429–440.
39. 39 Zhao, C., et al. Interferon-induced ISG15 pathway: an ongoing virus-host battle. Trends Microbiol. 21 (2013), 181–186.
40. 40 Morales, D.J., Lenschow, D.J., The antiviral activities of ISG15. J. Mol. Biol. 425 (2013), 4995–5008.
41. 41 Osiak, A., et al. ISG15, an interferon-stimulated ubiquitin-like protein, is not essential for STAT1 signaling and responses against vesicular stomatitis and lymphocytic choriomeningitis virus. Mol. Cell Biol. 25 (2005), 6338–6345.
42. 42 Kim, K.I., et al. Ube1L and protein ISGylation are not essential for alpha/beta interferon signaling. Mol. Cell Biol. 26 (2006), 472–479.
43. 43 Kim, J.H., et al. The level of hepatitis B virus replication is not affected by protein ISG15 modification but is reduced by inhibition of UBP43 (USP18) expression. J. Immunol. 181 (2008), 6467–6472.
44. 44 Lenschow, D.J., et al. Identification of interferon-stimulated gene 15 as an antiviral molecule during Sindbis virus infection in vivo. J. Virol. 79 (2005), 13974–13983.
45. 45 Lenschow, D.J., et al. IFN-stimulated gene 15 functions as a critical antiviral molecule against influenza, herpes, and Sindbis viruses. Proc. Natl. Acad. Sci. U.S.A. 104 (2007), 1371–1376.
46. 46 Giannakopoulos, N.V., et al. ISG15 Arg151 and the ISG15-conjugating enzyme UbE1L are important for innate immune control of Sindbis virus. J. Virol. 83 (2009), 1602–1610.
47. 47 Zhang, Y., et al. Identification and characterization of interferon-induced proteins that inhibit alphavirus replication. J. Virol. 81 (2007), 11246–11255.
48. 48 Lai, C., et al. Mice lacking the ISG15 E1 enzyme UbE1L demonstrate increased susceptibility to both mouse-adapted and non-mouse-adapted influenza B virus infection. J. Virol. 83 (2009), 1147–1151.
49. 49 Guerra, S., et al. Vaccinia virus E3 protein prevents the antiviral action of ISG15. PLoS Pathog., 4, 2008, e1000096.
50. 50 Rodriguez, M.R., et al. ISG15 functions as an interferon-mediated antiviral effector early in the murine norovirus life cycle. J. Virol. 88 (2014), 9277–9286.
51. 51 Werneke, S.W., et al. ISG15 is critical in the control of Chikungunya virus infection independent of UbE1L mediated conjugation. PLoS Pathog., 7, 2011, e1002322.
52. 52 Dai, J., et al. ISG15 facilitates cellular antiviral response to Dengue and West Nile virus infection in vitro. Virol J., 8, 2011, 468.
53. 53 Malakhova, O.A., Zhang, D.E., ISG15 inhibits Nedd4 ubiquitin E3 activity and enhances the innate antiviral response. J. Biol. Chem. 283 (2008), 8783–8787.
54. 54 Okumura, A., et al. Innate antiviral response targets HIV-1 release by the induction of ubiquitin-like protein ISG15. Proc. Natl. Acad. Sci. U.S.A. 103 (2006), 1440–1445.
55. 55 Pincetic, A., et al. The interferon-induced gene ISG15 blocks retrovirus release from cells late in the budding process. J. Virol. 84 (2010), 4725–4736.
56. 56 Wu, H.M., et al. [HIV-1 infection up-regulating expression of interferon-stimulated gene 15 in cell lines]. Bing Du Xue Bao. 29 (2013), 480–487.
57. 57 Woods, M.W., et al. Human HERC5 restricts an early stage of HIV-1 assembly by a mechanism correlating with the ISGylation of Gag. Retrovirology, 8, 2011, 95.
58. 58 Okumura, A., et al. ISG15 inhibits Ebola VP40 VLP budding in an L-domain-dependent manner by blocking Nedd4 ligase activity. Proc. Natl. Acad. Sci. U.S.A. 105 (2008), 3974–3979.
59. 59 Kuang, Z., et al. Mechanism of inhibition of retrovirus release from cells by interferon-induced gene ISG15. J. Virol. 85 (2011), 7153–7161.
60. 60 Hsiang, T.Y., et al. Interferon-induced ISG15 conjugation inhibits influenza A virus gene expression and replication in human cells. J. Virol. 83 (2009), 5971–5977.
61. 61 Tang, Y., et al. Herc5 attenuates influenza A virus by catalyzing ISGylation of viral NS1 protein. J. Immunol. 184 (2010), 5777–5790.
62. 62 Zhao, C., et al. Influenza B virus non-structural protein 1 counteracts ISG15 antiviral activity by sequestering ISGylated viral proteins. Nat. Commun., 7, 2016, 12754.
63. 63 Chua, P.K., et al. Modulation of alpha interferon anti-hepatitis C virus activity by ISG15. J. Gen. Virol. 90:Pt 12 (2009), 2929–2939.
64. 64 Broering, R., et al. The interferon stimulated gene 15 functions as a proviral factor for the hepatitis C virus and as a regulator of the IFN response. Gut 59 (2010), 1111–1119.
65. 65 Kim, M.J., Yoo, J.Y., Inhibition of hepatitis C virus replication by IFN-mediated ISGylation of HCV-NS5A. J. Immunol. 185 (2010), 4311–4318.
66. 66 Ketscher, L., et al. Selective inactivation of USP18 isopeptidase activity in vivo enhances ISG15 conjugation and viral resistance. Proc. Natl. Acad. Sci. U.S.A. 112 (2015), 1577–1582.
67. 67 Ritchie, K.J., et al. Role of ISG15 protease UBP43 (USP18) in innate immunity to viral infection. Nat. Med. 10 (2004), 1374–1378.
68. 68 Ma, X.Z., et al. Protein interferon-stimulated gene 15 conjugation delays but does not overcome coronavirus proliferation in a model of fulminant hepatitis. J. Virol. 88 (2014), 6195–6204.
69. 69 Zaheer, R.S., et al. Human rhinovirus-induced ISG15 selectively modulates epithelial antiviral immunity. Mucosal Immunol. 7 (2014), 1127–1138.
70. 70 Hishiki, T., et al. Interferon-mediated ISG15 conjugation restricts Dengue virus 2 replication. Biochem. Biophys. Res. Commun. 448 (2014), 95–100.
71. 71 Jones, D.M., et al. Comparison of U2OS and Huh-7 cells for identifying host factors that affect hepatitis C virus RNA replication. J. Gen. Virol. 91:Pt 9 (2010), 2238–2248.
72. 72 Domingues, P., et al. Inhibition of hepatitis C virus RNA replication by ISG15 does not require its conjugation to protein substrates by the HERC5 E3 ligase. J. Gen. Virol. 96 (2015), 3236–3242.
73. 73 Hsiao, N.W., et al. ISG15 over-expression inhibits replication of the Japanese encephalitis virus in human medulloblastoma cells. Antiviral Res. 85 (2010), 504–511.
74. 74 Jacobs, S.R., et al. Kaposi's Sarcoma-Associated Herpesvirus Viral Interferon Regulatory Factor 1 Interacts with a Member of the Interferon-Stimulated Gene 15 Pathway. J. Virol. 89 (2015), 11572–11583.
75. 75 Tian, J., et al. Blocking the PI3K/AKT pathway enhances mammalian reovirus replication by repressing IFN-stimulated genes. Front Microbiol., 6, 2015, 886.
76. 76 Shi, H.X., et al. Positive regulation of interferon regulatory factor 3 activation by Herc5 via ISG15 modification. Mol. Cell Biol. 30 (2010), 2424–2436.
77. 77 Chen, L., et al. ISG15, a ubiquitin-like interferon-stimulated gene, promotes hepatitis C virus production in vitro: implications for chronic infection and response to treatment. J. Gen. Virol. 91:Pt 2 (2010), 382–388.
78. 78 Arimoto, K., et al. Murine Herc6 Plays a Critical Role in Protein ISGylation In Vivo and Has an ISGylation-Independent Function in Seminal Vesicles. J. Interferon. Cytokine. Res. 35 (2015), 351–358.
79. 79 Lu, G., et al. ISG15 enhances the innate antiviral response by inhibition of IRF-3 degradation. Cell Mol. Biol. (Noisy-le-grand) 52 (2006), 29–41.